SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Suven Life Sciences - Quaterly Results

24 Jan 2025 Evaluate
The sales moved down -34.31% to Rs. 16.10 millions for the December 2024 quarter as compared to Rs. 24.51 millions during the corresponding quarter last year.The Net Loss for the quarter ended December 2024 is Rs. -132.73 millions as compared to Net Loss of Rs. -47.69 millions of corresponding quarter ended December 2023 Operating profit Margin for the quarter ended December 2024 further decreased to -117.31% as compared to -31.33% of corresponding quarter ended December 2023


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202412 202312 % Var 202412 202312 % Var 202403 202303 % Var
Sales 16.10 24.51 -34.31 51.89 93.08 -44.25 116.93 135.39 -13.63
Other Income 15.69 60.66 -74.13 95.35 168.48 -43.41 211.30 84.49 150.09
PBIDT -117.31 -31.33 274.43 -274.89 -72.22 280.63 -98.07 -192.95 -49.17
Interest 0.08 0.35 -77.14 0.47 1.28 -63.28 1.58 2.89 -45.33
PBDT -117.39 -31.68 270.55 -275.36 1.07 -25834.58 -25.08 -135.84 -81.54
Depreciation 15.34 16.01 -4.18 44.75 49.91 -10.34 65.02 65.43 -0.63
PBT -132.73 -47.69 178.32 -320.11 -48.84 555.43 -90.10 -201.27 -55.23
TAX 0.00 0.00 0.00 0.00 0.00 0.00 -10.02 0.00 0.00
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PAT -132.73 -47.69 178.32 -320.11 -48.84 555.43 -80.08 -201.27 -60.21
Equity 218.07 218.07 0.00 218.07 218.07 0.00 218.07 218.07 0.00
PBIDTM(%) -728.63 -127.83 470.02 -529.76 -77.59 582.77 -83.87 -142.51 -41.15

Suven Life Sciences Share Price

195.90 -0.10 (-0.05%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×